Interaction of the new inhibitor paxlovid (PF-07321332) and ivermectin with the monomer of the main protease SARS-CoV-2: A volumetric study based on molecular dynamics, elastic networks, classical thermodynamics and SPT새로운 억제제 paxlovid(PF-07321332)와 이버멕틴과 주요 프로테아제 SARS-CoV-2의 단량체와의 상호 작용: 분자 역학, 탄성 네트워크, 고전적 열역학 및 SPT를 기반으로 한 체적 연구Article Published on 2022-08-012022-09-11 Journal: Computational biology and chemistry [Category] COVID19(2023년), MERS, SARS, 진단, 치료제, [키워드] accelerated ANM bind binding binding site blind catalytic catalytic site catalytic sites classical clinical trial clinical trials complex complexes covalent binding COVID-19 COVID-19 pandemic docking drugs electric dipole moment feasible flexible fluctuation fluctuations form GNM homologue inhibitor Interaction intrinsic involved Ivermectin ivermectin B1a M pro molecular molecular dynamics molecular mechanism monomer Paxlovid PF-07321332 protease Protein Region reported scaled SPT structural flexibility Support Viral Volume Volume fluctuation Volume Molar volumetric Voronoi. [DOI] 10.1016/j.compbiolchem.2022.107692 PMC 바로가기 [Article Type] Article
Inappropriate use of ivermectin during the COVID-19 pandemic: primum non nocere!Discussion Published on 2022-07-012022-10-05 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), SARS, 신약개발, [키워드] clinical COVID-19 ESCMID guidelines Ivermectin Treatment [DOI] 10.1016/j.cmi.2022.03.022 [Article Type] Discussion
Ivermectin for preventing and treating COVID-19COVID-19 예방 및 치료를 위한 이버멕틴Review Published on 2022-06-212022-09-11 Journal: The Cochrane database of systematic reviews [Category] COVID19(2023년), SARS, 임상, [키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition Admission adverse event adverse events all-cause mortality antiparasitic Antiviral approach ARMS Asymptomatic certainty certainty of evidence citation classification Clinical improvement clinical trial Cochrane COVID-19 Study Register coronavirus coronavirus disease COVID-19 COVID-19 diagnosis COVID-19 symptoms COVID-19 treatment Data collection database death discharged disease disease severity double-blind duration of symptom early stage early stages Efficacy Efficacy and safety eligible Evidence excluded for inclusion GRADE hospital identify in vitro include increase index Infection infection with SARS-CoV-2 inhibit inhibitory effect initial symptom Inpatient Inpatients Intervention Invasive mechanical ventilation investigated Ivermectin life mean difference Mental Meta-analysis Mild Moderate COVID-19 moderate-to-severe COVID-19 molecular hypothesis Mortality no effect non-randomized ongoing trial ongoing trials Open-label outcome Outpatient outpatients participant Participants people with COVID-19 physical Placebo placebo-controlled Postexposure Prophylaxis Prevent Quality of life question Randomized controlled trial Randomized controlled trials RCT RCTs receiving reduce Registered Replication Reporting request Research resolved risk Risk of bias risk ratio RoB 2 SARS-CoV-2 SARS-COV-2 infection Science Citation Index searched Selection Serious Adverse Event Serious Adverse Events Seven severe acute respiratory syndrome Coronavirus Standard of care treat treated treating COVID-19 Treatment Trial trials viral clearance virus Web of Science WHO WHO guideline worsening [DOI] 10.1002/14651858.CD015017.pub3 PMC 바로가기 [Article Type] Review
Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug combinations용도 변경 구충제 조합의 상승적 항 SARS-CoV-2 활성Article Published on 2022-06-182022-09-11 Journal: BMC Pharmacology & Toxicology [Category] COVID19(2023년), SARS, 신약개발, 치료제, [키워드] Analysis anti-parasitic drug Anti-parasitic drugs Anti-SARS-CoV-2 Activity antiviral drug antiviral drugs approach benefit Calu Calu-3 calu-3 cells Chloroquine claimed clinical trials Combination combinations country COVID-19 pandemic demonstrated drug drug combination drug combinations drugs Economy effective Effectiveness ENhance epithelial cells evaluated Health Service highest in vitro inhibitory inhibitory concentration Ivermectin Lung epithelial cells niclosamide pandemic reduction in Repurposed drug repurposing resulting SARS-CoV-2 shown Spread synergistic synergy tested Treatment vaccination Vero E6 Vero E6 cell VERO E6 cells [DOI] 10.1186/s40360-022-00580-8 PMC 바로가기 [Article Type] Article
Changes in dispensing of medicines proposed for re-purposing in the first year of the COVID-19 pandemic in AustraliaArticle Published on 2022-06-152022-10-04 Journal: PLoS ONE [Category] 신약개발, [키워드] 95%CI Analysis average change changes in Characteristics Colchicine Corticosteroid Corticosteroids COVID-19 COVID-19 pandemic cross-sectional Dispensing effective Evidence expected help Hydroxychloroquine increase increase in increases in Ivermectin limit media Medicine Medicines Other Pandemics Patient perceived benefit performed Practitioner Prevent quantified Regulatory sustained therapeutic understanding Vitamin D while [DOI] 10.1371/journal.pone.0269482 PMC 바로가기 [Article Type] Article
COVID-19 update: NIH recommends against ivermectinArticle Published on 2022-06-132023-07-09 Journal: The Medical letter on drugs and therapeutics [Category] COVID19(2023년), [키워드] bebtelovimab COVID-19 Efficacy Ivermectin Lagevrio molnupiravir Nirmatrelvir Paxlovid Remdesivir Ritonavir Veklury
Clinical update on COVID-19 for the emergency and critical care clinician: Medical management응급 및 중환자 진료의를 위한 COVID-19에 대한 임상 업데이트: 의료 관리Review Published on 2022-06-012022-09-11 Journal: The American journal of emergency medicine [Category] COVID19(2023년), SARS, 임상, 치료제, [키워드] 2019 acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition Admitted Patient antagonists antivirals Aspirin Care caused Chloroquine clinical clinician Clinicians Colchicine concerning convalescent plasma coronavirus coronavirus disease Coronavirus-2019 COVID-19 Critical care demonstrated disease Emergency Famotidine help Hydroxychloroquine IMPROVE interleukin interleukin-6 introduced Ivermectin kinase inhibitors management mineral Minerals monoclonal antibodies morbidity and mortality outcomes Outpatient outpatients pandemic Patient patients progressed prophylactic anticoagulation provide Randomized respiratory SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 Steroids Therapies therapy utility variety Vitamin vitamins with COVID-19 [DOI] 10.1016/j.ajem.2022.03.036 PMC 바로가기 [Article Type] Review
The effect of Ivermectin on cases of COVID-19Correspondence Published on 2022-06-012022-10-05 Journal: Cardiovascular revascularization medicine : includ [Category] 치료제, [키워드] Adult patient Antiviral Care Cohort COVID-19 COVID-19 infection Efficacy and safety evaluate evaluated increasingly Infection information Inpatient Ivermectin media Mortality Outpatient Patient patients with COVID-19 Treatment variety [DOI] 10.1016/j.carrev.2022.06.004 [Article Type] Correspondence
An internet-based cross-sectional study on infection control practices and drug use for COVID-19 prevention in Nigerian adultsArticle Published on 2022-06-012023-07-10 Journal: The Pan African Medical Journal [Category] COVID19(2023년), [키워드] Anti-bacterial agents Antimalarials COVID-19 infection control Ivermectin Masks Nigeria pharmaceutical preparations plant preparations. [DOI] 10.11604/pamj.2022.42.85.31596 PMC 바로가기
Recommendations for the Outpatient Drug Treatment of Patients With COVID-19Article Published on 2022-05-132022-11-15 Journal: Deutsches Ärzteblatt international [Category] 진단, [키워드] Acetylsalicylic acid carried Clinical efficacy clinically Colchicine college concerning conducted Consensus Course COVID-19 COVID-19 outpatient COVID-19 patient dose drug drug treatment early phase Elderly patient Evidence expected family general practitioner high risk Hospitalization in vitro Infection Ivermectin off-label offered Outpatient Patient patient selection physician Prevent primary care Prophylaxis Randomized controlled trial recommendation reduced Remdesivir response to vaccination retrieved risk risk factor severe disease course systemic steroids the disease treated Treatment treatment for COVID-19 Trial with COVID-19 [DOI] 10.3238/arztebl.m2022.0203 PMC 바로가기